The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression
Open accessAbstract
The Wilms' tumor gene WT1 is overexpressed in leukemias and various types of solid tumors, and the WT1 protein was demonstrated to be an attractive target antigen for immunotherapy against these malignancies. Here, we report the outcome of a phase I clinical study of WT1 peptide-based immunotherapy for patients with breast or lung cancer, myelodysplastic syndrome, or acute myeloid leukemia. Patients were intradermally injected with an HLA-A*2402-restricted, natural, or modified 9-mer WT1 peptide emulsified with Montanide ISA51 adjuvant at 0.3, 1.0, or 3.0 mg per body at 2-week intervals, with toxicity and clinical and immunological responses as the principal endpoints. Twenty-six patients received one or more WT1 vaccinations, and 18 of the 26 patients completed WT1 vaccination protocol with three or more injections of WT1 peptides. Toxicity consisted only of local erythema at the WT1 vaccine injection sites in patients with breast or lung cancer or acute myeloid leukemia with adequate normal hematopoiesis, whereas severe leukocytopenia occurred in patients with myelodysplastic syndrome with abnormal hematopoiesis derived from WT1-expressing, transformed hematopoietic stem cells. Twelve of the 20 patients for whom the efficacy of WT1 vaccination could be assessed showed clinical responses such as reduction in leukemic blast cells or tumor sizes and/or tumor markers. A clear correlation was observed between an increase in the frequencies of WT1-specific cytotoxic T lymphocytes after WT1 vaccination and clinical responses. It was therefore demonstrated that WT1 vaccination could induce WT1-specific cytotoxic T lymphocytes and result in cancer regression without damage to normal tissues.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Call, K. M., Glaser, T., Ito, C. Y., Buckler, A. J., Pelletier, J., Haber, D. A., Rose, E. A., Kral, A., Yeger, H., Lewis, W. H., et al. (1990) · Cell · doi:10.1016/0092-8674(90)90601-a · Cited by 1,876
Homozygous deletion in Wilms tumours of a zinc-finger gene identified by chromosome jumping
Gessler, M., Poustka, A., Cavenee, W., Neve, R. L., Orkin, S. H., & Bruns, G. A. P. (1990) · Nature · doi:10.1038/343774a0 · Cited by 1,292
Inoue, K., Sugiyama, H., Ogawa, H., Nakagawa, M., Yamagami, T., Miwa, H., Kita, K., Hiraoka, A., Masaoka, T., & Nasu, K. (1994) · Blood · doi:10.1182/blood.v84.9.3071.3071 · Cited by 575
Self-citationRepression of the Insulin-Like Growth Factor II Gene by the Wilms Tumor Suppressor WT1
Drummond, L. A., Madden, S. L., Rohwer-Nutter, P., Bell, G. I., Sukhatme, V. P., & Rauscher, F. J. (1992) · Science · doi:10.1126/science.1323141 · Cited by 525
Jäger, E., Gnjatic, S., Nagata, Y., Stockert, E., Jäger, D., Karbach, J., Neumann, A., Rieckenberg, J., Chen, Y.-T., Ritter, G., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.220413497 · Cited by 426
Selective elimination of leukemic CD34+ progenitor cells by cytotoxic T lymphocytes specific for WT1
Gao, L., Bellantuono, I., Elsässer, A., Marley, S. B., Gordon, M. Y., Goldman, J. M., & Stauss, H. J. (2000) · Blood · doi:10.1182/blood.v95.7.2198 · Cited by 408
Bergmann, L., Miething, C., Maurer, U., Brieger, J., Karakas, T., Weidmann, E., & Hoelzer, D. (1997) · Blood · doi:10.1182/blood.v90.3.1217 · Cited by 354
Ohminami, H., Yasukawa, M., & Fujita, S. (2000) · Blood · doi:10.1182/blood.v95.1.286 · Cited by 347
WT1 suppresses synthesis of the epidermal growth factor receptor and induces apoptosis.
Englert, C., Hou, X., Maheswaran, S., Bennett, P., Ngwu, C., Re, G. G., Garvin, A. J., Rosner, M. R., & Haber, D. A. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb00148.x · Cited by 330
Slingluff, C. L., Petroni, G. R., Yamshchikov, G. V., Barnd, D. L., Eastham, S., Galavotti, H., Patterson, J. W., Deacon, D. H., Hibbitts, S., Teates, D., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.005 · Cited by 322
Menssen, H. D., Renkl, H., Rodeck, U., et al. (1995) · PubMed · Cited by 264
Yamagami, T., Sugiyama, H., Inoue, K., Ogawa, H., Tatekawa, T., Hirata, M., Kudoh, T., Akiyama, T., Murakami, A., & Maekawa, T. (1996) · Blood · doi:10.1182/blood.v87.7.2878.bloodjournal8772878 · Cited by 251
Self-citationScheibenbogen, C., Letsch, A., Thiel, E., Schmittel, A., Mailaender, V., Baerwolf, S., Nagorsen, D., & Keilholz, U. (2002) · Blood · doi:10.1182/blood-2002-01-0163 · Cited by 248
Oka, Y., Elisseeva, O. A., Tsuboi, A., Ogawa, H., Tamaki, H., Li, H., Oji, Y., Kim, E. H., Soma, T., Asada, M., et al. (2000) · Immunogenetics · doi:10.1007/s002510050018 · Cited by 245
Self-citationNilsson, L., Åstrand-Grundström, I., Arvidsson, I., Jacobsson, B., Hellström-Lindberg, E., Hast, R., & Jacobsen, S. E. W. (2000) · Blood · doi:10.1182/blood.v96.6.2012 · Cited by 241
Ogawa, H., Tamaki, H., Ikegame, K., Soma, T., Kawakami, M., Tsuboi, A., Kim, E. H., Hosen, N., Murakami, M., Fujioka, T., et al. (2003) · Blood · doi:10.1182/blood-2002-06-1831 · Cited by 228
Self-citationWang, F., Bade, E., Kuniyoshi, C., Spears, L., Jeffery, G., Marty, V., Groshen, S. G., & Weber, J. S. (1999) · PubMed · Cited by 219
Expression of the Wilms' Tumor Gene WT1 in Solid Tumors and Its Involvement in Tumor Cell Growth
Oji, Y., Ogawa, H., Tamaki, H., Oka, Y., Tsuboi, A., Kim, E. H., Soma, T., Tatekawa, T., Kawakami, M., Asada, M., et al. (1999) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1999.tb00733.x · Cited by 208
Self-citationOverexpression of the Wilms' tumor gene WT1 in de novo lung cancers
Oji, Y., Miyoshi, S., Maeda, H., Hayashi, S., Tamaki, H., Nakatsuka, S., Yao, M., Takahashi, E., Nakano, Y., Hirabayashi, H., et al. (2002) · International Journal of Cancer · doi:10.1002/ijc.10476 · Cited by 201
Self-citationRegulation of the proto-oncogenes bcl-2 and c-myc by the Wilms' tumor suppressor gene WT1.
Hewitt, S. M., Hamada, S., McDonnell, T. J., Rauscher, F. J., & Saunders, G. F. (1995) · PubMed · Cited by 200
Tamaki, H., Ogawa, H., Ohyashiki, K., Ohyashiki, J., Iwama, H., Inoue, K., Soma, T., Oka, Y., Tatekawa, T., Oji, Y., et al. (1999) · Leukemia · doi:10.1038/sj.leu.2401341 · Cited by 181
Self-citationInoue, K., Tamaki, H., Ogawa, H., Oka, Y., Soma, T., Tatekawa, T., Oji, Y., Tsuboi, A., Kim, E. H., Kawakami, M., et al. (1998) · Blood · doi:10.1182/blood.v91.8.2969.2969_2969_2976 · Cited by 169
Self-citationImmunity to WT1 in the animal model and in patients with acute myeloid leukemia
Gaiger, A., Reese, V. A., Disis, M. L., & Cheever, M. A. (2000) · Blood · doi:10.1182/blood.v96.4.1480 · Cited by 142
Oka, Y., Tsuboi, A., Murakami, M., Hirai, M., Tominaga, N., Nakajima, H., Elisseeva, O. A., Masuda, T., Nakano, A., Kawakami, M., et al. (2003) · International Journal of Hematology · doi:10.1007/bf02983241 · Cited by 124
Self-citationTsuboi, A., Oka, Y., Udaka, K., Murakami, M., Masuda, T., Nakano, A., Nakajima, H., Yasukawa, M., Hiraki, A., Oji, Y., et al. (2002) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-002-0328-9 · Cited by 120
Self-citationElisseeva, O. A., Oka, Y., Tsuboi, A., Ogata, K., Wu, F., Kim, E. H., Soma, T., Tamaki, H., Kawakami, M., Oji, Y., et al. (2002) · Blood · doi:10.1182/blood.v99.9.3272 · Cited by 119
Self-citationHosen, N., Sonoda, Y., Oji, Y., Kimura, T., Minamiguchi, H., Tamaki, H., Kawakami, M., Asada, M., Kanato, K., Motomura, M., et al. (2002) · British Journal of Haematology · doi:10.1046/j.1365-2141.2002.03261.x · Cited by 118
Self-citationBrieger, J., Weidmann, E., Fenchel, K., Mitrou, P. S., Hoelzer, D. T., & Bergmann, L. (1994) · PubMed · Cited by 116
Functional Heterogeneity of Vaccine-Induced CD8+ T Cells
Monsurrò, V., Nagorsen, D., Wang, E., Provenzano, M., Dudley, M. E., Rosenberg, S. A., & Marincola, F. M. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.11.5933 · Cited by 88
Cytotoxic T-Lymphocyte Responses Elicited to Wilms' Tumor Gene WT1 Product by DNA Vaccination
Tsuboi, A., Oka, Y., Ogawa, H., Elisseeva, O. A., Li, H., Kawasaki, K., Aozasa, K., Kishimoto, T., Udaka, K., & Sugiyama, H. (2000) · Journal of Clinical Immunology · doi:10.1023/a:1006637529995 · Cited by 77
Self-citation
Cited by
Cancer vaccines: the next immunotherapy frontier
Lin, M. J., Svensson-Arvelund, J., Lubitz, G. S., Marabelle, A., Melero, I., Brown, B. D., & Brody, J. D. (2022) · Nature Cancer · doi:10.1038/s43018-022-00418-6 · Cited by 843
Therapeutic vaccines for cancer: an overview of clinical trials
Melero, I., Gaudernack, G., Gerritsen, W., Huber, C., Parmiani, G., Scholl, S., Thatcher, N., Wagstaff, J., Zielinski, C., Faulkner, I., et al. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.111 · Cited by 776
Nanotechnology in vaccine delivery
Peek, L. J., Middaugh, C. R., & Berkland, C. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.05.017 · Cited by 562
Van Tendeloo, V. F., Van de Velde, A., Van Driessche, A., Cools, N., Anguille, S., Ladell, K., Gostick, E., Vermeulen, K., Pieters, K., Nijs, G., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1008051107 · Cited by 377
Self-citationThe many facets of the Wilms' tumour gene, WT1
Hohenstein, P., & Hastie, N. D. (2006) · Human Molecular Genetics · doi:10.1093/hmg/ddl196 · Cited by 348
Metadata
- Authors
- Oka, Y., Tsuboi, A., Taguchi, T., Osaki, T., Kyo, T., Nakajima, H., Elisseeva, O. A., Oji, Y., Kawakami, M., Ikegame, K., Hosen, N., Yoshihara, S., Wu, F., Fujiki, F., Murakami, M., Masuda, T., Nishida, S., Shirakata, T., Nakatsuka, S.-I., Sasaki, A., Udaka, K., Dohy, H., Aozasa, K., Noguchi, S., Kawase, I., & Sugiyama, H.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2004-09-13
- Volume
- 101
- Issue
- 38
- Pages
- 13885-13890
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2161872048
- Cited by
- 531
- References
- 30
- FWCI
- 10.68
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.